Tag: Pure SNRI ((1S2R)-enantiomer)

  • Levomilnacipran

    Pure SNRI ((1S,2R)-enantiomer)

    The (1S,2R)-enantiomer of milnacipran; a pure SNRI with strong NET selectivity over SERT and minimal off-target activity.

    Abstract

    Levomilnacipran ((1S,2R)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide; CAS 96847-55-1 (HCl salt); molecular formula C15H22N2O; molecular weight 246.35) is the (1S,2R)-enantiomer of milnacipran, marketed as Fetzima by Forest Pharmaceuticals after FDA approval in 2013. Distinct among SNRIs for inverse selectivity: NET affinity (Ki approximately 11 nM) exceeds SERT affinity (Ki approximately 19 nM) by approximately 2-fold, the opposite of duloxetine and venlafaxine. The compound has minimal off-target activity at adrenergic, dopaminergic, muscarinic, or histaminergic sites. Plasma half-life is approximately 12 hours; metabolism is primarily renal (excreted unchanged) with minor CYP3A4 contribution, producing minimal drug-drug interaction potential. Approved for major depressive disorder; off-label investigation in attention deficit and chronic pain conditions. Used as the reference NET-selective SNRI in mechanism studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.